Holen Sie sich die Stockscreener-App
6.65
57.96%
2.44
Handel nachbörslich:
6.50
-0.15
-2.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.21
Offen:
$7.66
24-Stunden-Volumen:
65.82M
Relative Volume:
17.10
Marktkapitalisierung:
$385.11M
Einnahmen:
$11.13M
Nettoeinkommen (Verlust:
$-114.59M
KGV:
-2.8751
EPS:
-2.313
Netto-Cashflow:
$-113.96M
1W Leistung:
+62.59%
1M Leistung:
-67.84%
6M Leistung:
-70.38%
1J Leistung:
-14.52%
1-Tages-Spanne:
$6.04
$8.15
1-Wochen-Bereich:
$3.73
$8.15
52-Wochen-Spanne:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.65 | 242.65M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm - PR Newswire
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline - TMX Newsfile
Capricor Therapeutics (CAPR) Faces Class Action Scrutiny, Is The 88% Undervalued Case Credible? - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
Capricor Therapeutics (CAPR) Soars on Cantor Fitzgerald Upgrade Despite FDA Panel Setback - GuruFocus
Avoiding Lag: Real-Time Signals in (CAPR) Movement - Stock Traders Daily
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval - Sahm
Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And LawsuitsWhat's Changed - Yahoo Finance
Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy? - simplywall.st
Cantor Fitzgerald upgrades Capricor Therapeutics amid FDA review and strong cash position. - Pluang
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCAPR - ACCESS Newswire
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role - Barchart.com
CAPRICOR THERAPEUTICS, INC. 2026: Revenue $14.08M, EPS ($0.7) — 10-Q Summary - TradingView
Tang Capital group discloses 7.1% Capricor (CAPR) ownership in amended 13G - Stock Titan
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP - The AI Journal
CAPR Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Capricor Therapeutics (CAPR) Sees Surge Amid Deramiocel Update - GuruFocus
Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes - kwsn.com
Capricor Surges 67% as FDA Signals Openness to Revised Deramiocel Filing - finance.biggo.com
Capricor Therapeutics jumps 75% amid FDA talks on Duchenne Muscular Dystrophy drug update - pluang.com
Capricor: Stock Now Surging On Fresh BLA UpdatesWhat Investors Must Know (NASDAQ:CAPR) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why is Capricor Therapeutics stock surging today? - Investing.com
Capricor Shares Rise with FDA Review of Latest Duchenne Data, Eyes on August 22 Event - TechStock²
Capricor's DMD therapy deramiocel gets regulatory lifeline, shares surge - FirstWord Pharma
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data - Endpoints News
Capricor Therapeutics jumps as investors focus on ongoing FDA review and fresh deramiocel update - Quiver Quantitative
$Capricor Therapeutics (CAPR.US)$ - moomoo.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Capricor soars on plan to amend DMD filing after adcomm setback - Fierce Biotech
Why Is Capricor Therapeutics Stock Soaring Today?Capricor Therapeutics (NASDAQ:CAPR) - Benzinga
CAPR Stock In Focus As Lancet Data And Analyst Upgrades Collide - timothysykes.com
Capricor stock upgraded at Cantor on plans for lead drug (CAPR) - Seeking Alpha
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans - GuruFocus
CAPR Stock Draws Traders As Lancet Data And Big Upgrade Hit - StocksToTrade
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Capricor Therapeutics (CAPR) Rockets 115% Pre-Market Amid Valuation and Insider Activity Spotlight - GuruFocus
CAPRICOR THERAPEUTICS ($CAPR) Releases Q2 2026 Earnings - Moomoo
CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds - StocksToTrade
Why is Capricor Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Capricor surges on amended plans for lead drug (CAPR:NASDAQ) - Seeking Alpha
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - BNN Bloomberg
CAPR Upgraded by Cantor Fitzgerald -- Price Target Raised to $28.00 - GuruFocus
CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path - Yahoo Finance
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Why Is CAPR Stock Soaring Premarket? This Analyst Sees A New FDA Path For Deramiocel - Stocktwits
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):